SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the release for clinical use of its first clinical trial assay to support patient identification and enrollment into its STARTRK (“Studies of Tumor Alterations Responsive to Targeting Receptor Kinases”) clinical development program for entrectinib. Entrectinib is the company’s proprietary oral tyrosine kinase inhibitor, targeting tumors that harbor activating alterations to NTRK1/2/3 (encoding TrkA/TrkB/TrkC), ROS1 or ALK.
Help employers find you! Check out all the jobs and post your resume.
